Inclusology is a robust comprehensive DEI management SaaS platform with a mission to foster workplace inclusivity and combat bias, ultimately enhancing employee retention. Recently, the platform unveiled its latest version, following a successful beta testing phase involving 16 diverse companies and thousands of employees spanning startups, nonprofits, Fortune 500, and Fortune 1000 enterprises, among others.
Dr. Cheryl Ingram, the CEO of Inclusology, expressed pride in the platform’s global impact on DEI initiatives across organisations of all sizes. She emphasised the uniqueness of their approach, which leverages demographic data to conduct in-depth Diversity, Equity, and Inclusion (DEI) assessments. In addition to analysis and reporting, Inclusology offers benchmarking, e-learning, development opportunities, certifications, and personalised recommendations to address DEI challenges. Their distinctive approach integrates DEI seamlessly into an organisation’s culture, rather than treating it as a standalone initiative or program.
Notable outcomes from the beta testing phase included an impressive up to 75% increase in employee retention and a notable up to 25% improvement in diverse employee recruitment within a single year.
Inclusology, which spent the last five years in beta development, offers a comprehensive DEI solution that includes:
Inclusology’s overarching objective is to create a platform that accommodates individuals of all backgrounds and identities, fostering a secure and enjoyable work environment.
About Inclusology: Founded in 2018 by Dr. Cheryl Ingram, Inclusology initiated its first alpha test in 2019. Over the years, it has conducted assessments for renowned companies like Netflix and Parametrix. Originally based in Seattle, the company has since relocated its headquarters to Omaha, Nebraska. Presently, Inclusology employs a dedicated team of five professionals with extensive collective experience. The company’s core mission remains centered on creating an all-inclusive and safe workplace for everyone.